Drug Search Results
More Filters [+]

Omiganan

Alternative Names: omiganan, cls-001, Maruho, cls001, Maruho, cls 001,Maruho, MBI 226, MBI-226, MBI226
Latest Update: 2023-10-03
Latest Update Note: PubMed Publication

Product Description

Omiganan, a bactericidal and fungicidal cationic peptide being developed as a topical gel for prevention of catheter-associated infections, inhibited commonly occurring fungal pathogens.

Mechanisms of Action: IFN Modulator

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Maruho
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Omiganan

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Dermatitis, Seborrheic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2017-003106-41

P2

Active, not recruiting

Dermatitis, Seborrheic

2020-03-05

Recent News Events